Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
出版年份 2023 全文链接
标题
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
作者
关键词
-
出版物
Cancers
Volume 15, Issue 6, Pages 1744
出版商
MDPI AG
发表日期
2023-03-14
DOI
10.3390/cancers15061744
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
- (2022) Laura Spring et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
- (2022) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
- (2021) E.B. Garon et al. ANNALS OF ONCOLOGY
- O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
- (2021) Toshio Shimizu et al. ANNALS OF ONCOLOGY
- ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer
- (2021) Weiyu Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.
- (2020) Yongheng Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells
- (2017) Bin Wu et al. Experimental and Therapeutic Medicine
- TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT
- (2017) Xinxing Li et al. Oncotarget
- Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer
- (2017) Wei Zhao et al. Cancer Medicine
- Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas
- (2017) Peng Xu et al. Cancer Management and Research
- Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
- (2016) Emanuela Guerra et al. CLINICAL CANCER RESEARCH
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
- (2016) Jung Wook Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
- (2016) Ping Zeng et al. Scientific Reports
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Trop2: From development to disease
- (2015) Annie R.A. McDougall et al. DEVELOPMENTAL DYNAMICS
- siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells
- (2015) XIAO-YAN GAO et al. Experimental and Therapeutic Medicine
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
- (2015) Marco Trerotola et al. Oncotarget
- Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
- (2015) Nobuyuki Horita et al. Scientific Reports
- Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC
- (2015) Kaihua Zhang et al. Oncotarget
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts
- (2014) Catharina M. van Rij et al. MOLECULAR IMAGING AND BIOLOGY
- Trop-2 Promotes Prostate Cancer Metastasis By Modulating 1 Integrin Functions
- (2013) M. Trerotola et al. CANCER RESEARCH
- Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway
- (2013) H Nakanishi et al. ONCOGENE
- Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway
- (2013) Ting Liu et al. PLoS One
- Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells
- (2013) T. Stoyanova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain
- (2013) Tilen Vidmar et al. PROTEIN EXPRESSION AND PURIFICATION
- TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
- (2012) Jau-Chen Lin et al. EMBO Molecular Medicine
- Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer
- (2012) Hong Lin et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis
- (2012) Marco Trerotola et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers
- (2012) R. M. Sharkey et al. JOURNAL OF NUCLEAR MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- The Trop-2 signalling network in cancer growth
- (2012) E Guerra et al. ONCOGENE
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Loss of Trop2 Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous Cell Carcinoma
- (2011) J. Wang et al. MOLECULAR CANCER RESEARCH
- New Antibody Conjugates in Cancer Therapy
- (2011) Serengulam V. Govindan et al. TheScientificWorldJOURNAL
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium
- (2010) S. Memarzadeh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Cell of Origin for Human Prostate Cancer
- (2010) A. S. Goldstein et al. SCIENCE
- Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver
- (2009) M. Okabe et al. DEVELOPMENT
- TROP2 expression as prognostic marker for gastric carcinoma
- (2008) G Muhlmann et al. JOURNAL OF CLINICAL PATHOLOGY
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
- (2008) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics
- (2008) A. S. Goldstein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started